Dane Stevens & Optimi Health

Dane Stevens: Dane Stevens, CEO of Optimi Health, highlighted the significance of the production and export runs in expanding access to psychedelic treatments in Australia.

Optimi Health: Optimi Health completed the first 2026 production and export of MDMA and psilocybin capsules to Australia, expanding its market access for psychedelic treatments for PTSD and TRD.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, is leading the company's ibogaine initiative and highlights the growing interest and public funding for ibogaine research.

Optimi Health: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health Corp., announced the launch of the new microdose psilocybin products, highlighting their consistent dosage for controlled research.

Optimi Health: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, highlighted the significance of the company's first shipment to the United Kingdom and its unique position as a vertically integrated GMP supplier.

Optimi Health: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, expressed pride in the company's commercial supply of psilocybin and highlighted Australia's role as a model for regulated psychedelic medicine.

Optimi Health: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.